Share Price and Basic Stock Data
Last Updated: December 6, 2025, 9:31 pm
| PEG Ratio | 2.08 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Marksans Pharma Ltd operates in the dynamic pharmaceuticals sector, a space characterized by rapid innovation and regulatory challenges. As of March 2025, the company’s revenue from operations stood at ₹2,623 Cr, reflecting a robust growth trajectory from ₹1,852 Cr in the previous fiscal year. This upward trend is notable, especially when we consider that the company has consistently increased its sales over the quarters, with the latest quarter (Sep 2023) recording ₹531 Cr in sales, up from ₹500 Cr in Jun 2023. Such consistency in revenue growth illustrates Marksans’ ability to navigate market fluctuations and maintain its competitive edge. Furthermore, the company has shown resilience despite a backdrop of rising costs in the pharmaceutical industry, indicating effective management strategies in place.
Profitability and Efficiency Metrics
Profitability is a critical metric for investors, and Marksans appears to be on solid ground. The operating profit margin (OPM) for the fiscal year ending March 2025 was reported at 20%, a commendable figure that underscores the company’s operational efficiency. Notably, the net profit for the same period rose to ₹383 Cr, bolstered by a strategic focus on cost management and revenue enhancement. The interest coverage ratio (ICR) stands at a remarkable 51.37x, indicating that the company generates ample earnings to cover its interest obligations, a clear sign of financial health. However, it’s essential to monitor the cash conversion cycle, which has extended to 247 days in FY 2025. This lengthening could signal potential inefficiencies in inventory management or receivables collection, warranting attention from management to optimize working capital.
Balance Sheet Strength and Financial Ratios
Marksans Pharma’s balance sheet reflects a strong financial position, with total assets amounting to ₹3,240 Cr as of March 2025. The company’s borrowings are relatively low at ₹332 Cr, leading to a debt-to-equity ratio of just 0.01, indicating minimal reliance on external debt. This low leverage enhances the company’s financial stability and provides flexibility for future growth initiatives. Additionally, the company’s return on equity (ROE) is reported at 16.8%, which is quite appealing compared to industry averages. However, the price-to-book value ratio (P/BV) at 4.08x suggests that the stock may be trading at a premium, indicating that investors have high expectations of future growth. While this can be a positive signal, it also means that any missteps could lead to significant valuation corrections.
Shareholding Pattern and Investor Confidence
The shareholding structure of Marksans Pharma reveals a healthy mix of ownership among promoters, institutional investors, and the public. Promoters hold 43.87% of the company, which indicates a significant level of commitment and confidence in the business from its founders. Foreign institutional investors (FIIs) have increased their stake to 16.92%, showcasing growing investor interest in the company. This rise in FII participation, particularly from 4.23% in December 2022, signals a positive outlook from foreign investors who are often more cautious. However, the public shareholding has fluctuated, standing at 33.93%. While diverse shareholding can be beneficial, a declining public stake could raise concerns about liquidity and market sentiment. As the number of shareholders reached 2,65,788, this broad base may help in maintaining stability in the stock price.
Outlook, Risks, and Final Insight
Looking ahead, Marksans Pharma has several strengths and risks that investors should weigh carefully. On the strength side, the company’s consistent revenue growth and robust profitability metrics provide a solid foundation for future performance. Furthermore, low debt levels afford it the flexibility to invest in growth opportunities without the burden of high-interest obligations. However, risks remain, particularly related to its extended cash conversion cycle, which could impact liquidity and operational efficiency. Additionally, while the stock’s premium valuation may reflect optimism, it could also expose investors to the risk of sharp corrections should growth falter. In conclusion, while Marksans Pharma presents a compelling investment case based on its fundamentals, potential investors should remain vigilant about operational efficiencies and market dynamics that could influence the stock’s performance in the coming years.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Marksans Pharma Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 146 Cr. | 116 | 247/84.3 | 32.3 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,112 Cr. | 377 | 479/192 | 85.2 | 24.3 | 0.18 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.5 Cr. | 47.9 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 44.0 Cr. | 30.0 | 30.5/17.0 | 105 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,538.16 Cr | 1,170.18 | 51.88 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 434 | 453 | 480 | 486 | 500 | 531 | 586 | 560 | 591 | 642 | 682 | 708 | 620 |
| Expenses | 361 | 372 | 403 | 376 | 398 | 417 | 453 | 450 | 462 | 506 | 543 | 582 | 520 |
| Operating Profit | 73 | 80 | 77 | 110 | 102 | 114 | 133 | 110 | 128 | 136 | 139 | 127 | 100 |
| OPM % | 17% | 18% | 16% | 23% | 20% | 21% | 23% | 20% | 22% | 21% | 20% | 18% | 16% |
| Other Income | 16 | 14 | 18 | 11 | 10 | 19 | 5 | 17 | 15 | 11 | 28 | 15 | 6 |
| Interest | 2 | 3 | 2 | 2 | 2 | 2 | 3 | 5 | 3 | 3 | 3 | 3 | 6 |
| Depreciation | 11 | 14 | 13 | 14 | 14 | 18 | 22 | 21 | 20 | 20 | 21 | 23 | 23 |
| Profit before tax | 76 | 78 | 79 | 104 | 97 | 114 | 113 | 100 | 120 | 125 | 143 | 116 | 77 |
| Tax % | 21% | 23% | 21% | 21% | 27% | 26% | 26% | 23% | 26% | 22% | 27% | 22% | 24% |
| Net Profit | 60 | 60 | 62 | 83 | 70 | 84 | 83 | 78 | 89 | 98 | 105 | 91 | 58 |
| EPS in Rs | 1.46 | 1.51 | 1.57 | 1.81 | 1.52 | 1.84 | 1.84 | 1.73 | 1.96 | 2.13 | 2.31 | 2.00 | 1.29 |
Last Updated: August 20, 2025, 7:10 am
Below is a detailed analysis of the quarterly data for Marksans Pharma Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 620.00 Cr.. The value appears to be declining and may need further review. It has decreased from 708.00 Cr. (Mar 2025) to 620.00 Cr., marking a decrease of 88.00 Cr..
- For Expenses, as of Jun 2025, the value is 520.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 582.00 Cr. (Mar 2025) to 520.00 Cr., marking a decrease of 62.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 100.00 Cr.. The value appears to be declining and may need further review. It has decreased from 127.00 Cr. (Mar 2025) to 100.00 Cr., marking a decrease of 27.00 Cr..
- For OPM %, as of Jun 2025, the value is 16.00%. The value appears to be declining and may need further review. It has decreased from 18.00% (Mar 2025) to 16.00%, marking a decrease of 2.00%.
- For Other Income, as of Jun 2025, the value is 6.00 Cr.. The value appears to be declining and may need further review. It has decreased from 15.00 Cr. (Mar 2025) to 6.00 Cr., marking a decrease of 9.00 Cr..
- For Interest, as of Jun 2025, the value is 6.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3.00 Cr. (Mar 2025) to 6.00 Cr., marking an increase of 3.00 Cr..
- For Depreciation, as of Jun 2025, the value is 23.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 23.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 77.00 Cr.. The value appears to be declining and may need further review. It has decreased from 116.00 Cr. (Mar 2025) to 77.00 Cr., marking a decrease of 39.00 Cr..
- For Tax %, as of Jun 2025, the value is 24.00%. The value appears to be increasing, which may not be favorable. It has increased from 22.00% (Mar 2025) to 24.00%, marking an increase of 2.00%.
- For Net Profit, as of Jun 2025, the value is 58.00 Cr.. The value appears to be declining and may need further review. It has decreased from 91.00 Cr. (Mar 2025) to 58.00 Cr., marking a decrease of 33.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 1.29. The value appears to be declining and may need further review. It has decreased from 2.00 (Mar 2025) to 1.29, marking a decrease of 0.71.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:52 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 630 | 797 | 893 | 767 | 913 | 1,000 | 1,134 | 1,376 | 1,491 | 1,852 | 2,177 | 2,623 | 2,652 |
| Expenses | 512 | 612 | 757 | 722 | 834 | 868 | 942 | 1,037 | 1,232 | 1,513 | 1,719 | 2,094 | 2,151 |
| Operating Profit | 118 | 185 | 136 | 45 | 78 | 132 | 192 | 340 | 259 | 340 | 459 | 529 | 502 |
| OPM % | 19% | 23% | 15% | 6% | 9% | 13% | 17% | 25% | 17% | 18% | 21% | 20% | 19% |
| Other Income | 4 | 3 | 9 | 7 | 8 | 5 | 0 | 7 | 42 | 59 | 50 | 70 | 60 |
| Interest | 19 | 16 | 10 | 7 | 10 | 10 | 9 | 8 | 8 | 9 | 11 | 12 | 15 |
| Depreciation | 16 | 16 | 28 | 30 | 27 | 23 | 27 | 36 | 45 | 52 | 74 | 83 | 86 |
| Profit before tax | 86 | 156 | 107 | 15 | 50 | 104 | 157 | 302 | 248 | 338 | 424 | 504 | 461 |
| Tax % | 15% | 28% | 23% | 24% | 28% | 23% | 23% | 21% | 25% | 21% | 26% | 24% | |
| Net Profit | 74 | 112 | 83 | 11 | 36 | 80 | 121 | 239 | 187 | 265 | 315 | 383 | 352 |
| EPS in Rs | 1.87 | 2.67 | 1.92 | 0.22 | 0.80 | 1.87 | 2.95 | 5.76 | 4.51 | 5.88 | 6.92 | 8.40 | 7.73 |
| Dividend Payout % | 5% | 4% | 21% | 23% | 6% | 3% | 3% | 4% | 6% | 9% | 9% | 10% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 51.35% | -25.89% | -86.75% | 227.27% | 122.22% | 51.25% | 97.52% | -21.76% | 41.71% | 18.87% | 21.59% |
| Change in YoY Net Profit Growth (%) | 0.00% | -77.24% | -60.85% | 314.02% | -105.05% | -70.97% | 46.27% | -119.28% | 63.47% | -22.84% | 2.72% |
Marksans Pharma Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 18% |
| 3 Years: | 21% |
| TTM: | 17% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 26% |
| 3 Years: | 27% |
| TTM: | 5% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 30% |
| 3 Years: | 48% |
| 1 Year: | -34% |
| Return on Equity | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 19% |
| 3 Years: | 17% |
| Last Year: | 17% |
Last Updated: Unknown
Balance Sheet
Last Updated: December 4, 2025, 1:37 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 39 | 41 | 41 | 41 | 41 | 41 | 41 | 41 | 41 | 45 | 45 | 45 | 45 |
| Reserves | 90 | 326 | 401 | 392 | 430 | 502 | 595 | 846 | 1,161 | 1,700 | 2,020 | 2,422 | 2,643 |
| Borrowings | 173 | 101 | 100 | 110 | 118 | 100 | 30 | 34 | 111 | 123 | 244 | 322 | 332 |
| Other Liabilities | 188 | 207 | 180 | 209 | 142 | 160 | 236 | 307 | 323 | 322 | 372 | 451 | 422 |
| Total Liabilities | 490 | 676 | 722 | 752 | 731 | 802 | 902 | 1,228 | 1,636 | 2,190 | 2,681 | 3,240 | 3,442 |
| Fixed Assets | 146 | 166 | 270 | 267 | 279 | 270 | 303 | 309 | 428 | 486 | 776 | 982 | 1,054 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 3 | 10 | 9 | 27 | 7 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 27 | 1 | 1 |
| Other Assets | 344 | 510 | 452 | 484 | 451 | 533 | 599 | 907 | 1,205 | 1,694 | 1,869 | 2,230 | 2,381 |
| Total Assets | 490 | 676 | 722 | 752 | 731 | 802 | 902 | 1,228 | 1,636 | 2,190 | 2,681 | 3,240 | 3,442 |
Below is a detailed analysis of the balance sheet data for Marksans Pharma Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 45.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 45.00 Cr..
- For Reserves, as of Sep 2025, the value is 2,643.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,422.00 Cr. (Mar 2025) to 2,643.00 Cr., marking an increase of 221.00 Cr..
- For Borrowings, as of Sep 2025, the value is 332.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 322.00 Cr. (Mar 2025) to 332.00 Cr., marking an increase of 10.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 422.00 Cr.. The value appears to be improving (decreasing). It has decreased from 451.00 Cr. (Mar 2025) to 422.00 Cr., marking a decrease of 29.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 3,442.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3,240.00 Cr. (Mar 2025) to 3,442.00 Cr., marking an increase of 202.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 1,054.00 Cr.. The value appears strong and on an upward trend. It has increased from 982.00 Cr. (Mar 2025) to 1,054.00 Cr., marking an increase of 72.00 Cr..
- For CWIP, as of Sep 2025, the value is 7.00 Cr.. The value appears to be declining and may need further review. It has decreased from 27.00 Cr. (Mar 2025) to 7.00 Cr., marking a decrease of 20.00 Cr..
- For Investments, as of Sep 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
- For Other Assets, as of Sep 2025, the value is 2,381.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,230.00 Cr. (Mar 2025) to 2,381.00 Cr., marking an increase of 151.00 Cr..
- For Total Assets, as of Sep 2025, the value is 3,442.00 Cr.. The value appears strong and on an upward trend. It has increased from 3,240.00 Cr. (Mar 2025) to 3,442.00 Cr., marking an increase of 202.00 Cr..
Notably, the Reserves (2,643.00 Cr.) exceed the Borrowings (332.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -55.00 | 84.00 | 36.00 | -65.00 | -40.00 | 32.00 | 162.00 | 306.00 | 148.00 | 217.00 | 215.00 | 207.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 98 | 84 | 89 | 118 | 71 | 64 | 78 | 72 | 97 | 82 | 76 | 75 |
| Inventory Days | 102 | 107 | 120 | 151 | 152 | 215 | 155 | 248 | 216 | 192 | 217 | 270 |
| Days Payable | 83 | 88 | 85 | 129 | 54 | 78 | 71 | 103 | 102 | 91 | 94 | 98 |
| Cash Conversion Cycle | 118 | 103 | 124 | 140 | 169 | 202 | 163 | 217 | 211 | 183 | 199 | 247 |
| Working Capital Days | -13 | 17 | 59 | 77 | 70 | 97 | 87 | 104 | 121 | 122 | 129 | 142 |
| ROCE % | 37% | 44% | 23% | 4% | 10% | 18% | 25% | 38% | 23% | 22% | 21% | 20% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Bandhan Small Cap Fund | 3,335,509 | 0.35 | 60.73 | N/A | N/A | N/A |
| UTI Small Cap Fund | 2,518,039 | 0.93 | 45.85 | N/A | N/A | N/A |
| UTI Aggressive Hybrid Fund | 2,159,816 | 0.6 | 39.33 | 2,078,253 | 2025-12-08 01:26:44 | 3.92% |
| UTI Large & Mid Cap Fund | 2,019,995 | 0.7 | 36.78 | 1,082,611 | 2025-12-08 01:26:44 | 86.59% |
| UTI Healthcare Fund | 755,000 | 1.22 | 13.75 | 232,711 | 2025-12-08 01:26:44 | 224.44% |
| UTI Retirement Fund | 701,714 | 0.27 | 12.78 | 1,049,499 | 2025-12-08 01:26:44 | -33.14% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | 8.40 | 6.92 | 6.41 | 4.51 | 5.76 |
| Diluted EPS (Rs.) | 8.40 | 6.92 | 6.41 | 4.51 | 5.76 |
| Cash EPS (Rs.) | 10.28 | 8.59 | 7.00 | 5.66 | 6.71 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 54.44 | 46.03 | 38.95 | 29.88 | 22.12 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 54.44 | 46.03 | 38.95 | 29.88 | 22.12 |
| Revenue From Operations / Share (Rs.) | 57.88 | 48.05 | 40.87 | 36.42 | 33.62 |
| PBDIT / Share (Rs.) | 13.22 | 11.23 | 8.80 | 7.35 | 8.46 |
| PBIT / Share (Rs.) | 11.38 | 9.59 | 7.65 | 6.25 | 7.58 |
| PBT / Share (Rs.) | 11.12 | 9.35 | 7.45 | 6.05 | 7.38 |
| Net Profit / Share (Rs.) | 8.44 | 6.95 | 5.85 | 4.56 | 5.83 |
| NP After MI And SOA / Share (Rs.) | 8.40 | 6.92 | 5.88 | 4.56 | 5.83 |
| PBDIT Margin (%) | 22.83 | 23.37 | 21.52 | 20.17 | 25.16 |
| PBIT Margin (%) | 19.65 | 19.96 | 18.72 | 17.16 | 22.53 |
| PBT Margin (%) | 19.21 | 19.45 | 18.23 | 16.60 | 21.95 |
| Net Profit Margin (%) | 14.58 | 14.46 | 14.32 | 12.53 | 17.33 |
| NP After MI And SOA Margin (%) | 14.51 | 14.40 | 14.37 | 12.53 | 17.33 |
| Return on Networth / Equity (%) | 15.42 | 15.19 | 15.25 | 15.53 | 26.90 |
| Return on Capital Employeed (%) | 18.66 | 18.97 | 18.75 | 19.93 | 33.35 |
| Return On Assets (%) | 11.74 | 11.70 | 12.15 | 11.39 | 19.42 |
| Total Debt / Equity (X) | 0.01 | 0.01 | 0.02 | 0.03 | 0.02 |
| Asset Turnover Ratio (%) | 0.88 | 0.89 | 0.96 | 1.04 | 0.73 |
| Current Ratio (X) | 4.62 | 4.78 | 4.91 | 3.37 | 3.02 |
| Quick Ratio (X) | 2.85 | 3.19 | 3.49 | 2.18 | 1.67 |
| Inventory Turnover Ratio (X) | 3.58 | 1.21 | 1.35 | 1.30 | 1.74 |
| Dividend Payout Ratio (NP) (%) | 7.14 | 7.22 | 3.81 | 5.47 | 1.71 |
| Dividend Payout Ratio (CP) (%) | 5.86 | 5.84 | 3.19 | 4.41 | 1.49 |
| Earning Retention Ratio (%) | 92.86 | 92.78 | 96.19 | 94.53 | 98.29 |
| Cash Earning Retention Ratio (%) | 94.14 | 94.16 | 96.81 | 95.59 | 98.51 |
| Interest Coverage Ratio (X) | 51.37 | 45.43 | 43.67 | 35.61 | 43.36 |
| Interest Coverage Ratio (Post Tax) (X) | 33.81 | 29.11 | 30.07 | 23.12 | 30.87 |
| Enterprise Value (Cr.) | 9417.36 | 6244.01 | 2540.86 | 1577.14 | 1869.83 |
| EV / Net Operating Revenue (X) | 3.59 | 2.87 | 1.37 | 1.06 | 1.36 |
| EV / EBITDA (X) | 15.72 | 12.27 | 6.37 | 5.24 | 5.40 |
| MarketCap / Net Operating Revenue (X) | 3.84 | 3.15 | 1.72 | 1.25 | 1.49 |
| Retention Ratios (%) | 92.85 | 92.77 | 96.18 | 94.52 | 98.28 |
| Price / BV (X) | 4.08 | 3.33 | 1.83 | 1.55 | 2.31 |
| Price / Net Operating Revenue (X) | 3.84 | 3.15 | 1.72 | 1.25 | 1.49 |
| EarningsYield | 0.03 | 0.04 | 0.08 | 0.10 | 0.11 |
After reviewing the key financial ratios for Marksans Pharma Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 8.40. This value is within the healthy range. It has increased from 6.92 (Mar 24) to 8.40, marking an increase of 1.48.
- For Diluted EPS (Rs.), as of Mar 25, the value is 8.40. This value is within the healthy range. It has increased from 6.92 (Mar 24) to 8.40, marking an increase of 1.48.
- For Cash EPS (Rs.), as of Mar 25, the value is 10.28. This value is within the healthy range. It has increased from 8.59 (Mar 24) to 10.28, marking an increase of 1.69.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 54.44. It has increased from 46.03 (Mar 24) to 54.44, marking an increase of 8.41.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 54.44. It has increased from 46.03 (Mar 24) to 54.44, marking an increase of 8.41.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 57.88. It has increased from 48.05 (Mar 24) to 57.88, marking an increase of 9.83.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 13.22. This value is within the healthy range. It has increased from 11.23 (Mar 24) to 13.22, marking an increase of 1.99.
- For PBIT / Share (Rs.), as of Mar 25, the value is 11.38. This value is within the healthy range. It has increased from 9.59 (Mar 24) to 11.38, marking an increase of 1.79.
- For PBT / Share (Rs.), as of Mar 25, the value is 11.12. This value is within the healthy range. It has increased from 9.35 (Mar 24) to 11.12, marking an increase of 1.77.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 8.44. This value is within the healthy range. It has increased from 6.95 (Mar 24) to 8.44, marking an increase of 1.49.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 8.40. This value is within the healthy range. It has increased from 6.92 (Mar 24) to 8.40, marking an increase of 1.48.
- For PBDIT Margin (%), as of Mar 25, the value is 22.83. This value is within the healthy range. It has decreased from 23.37 (Mar 24) to 22.83, marking a decrease of 0.54.
- For PBIT Margin (%), as of Mar 25, the value is 19.65. This value is within the healthy range. It has decreased from 19.96 (Mar 24) to 19.65, marking a decrease of 0.31.
- For PBT Margin (%), as of Mar 25, the value is 19.21. This value is within the healthy range. It has decreased from 19.45 (Mar 24) to 19.21, marking a decrease of 0.24.
- For Net Profit Margin (%), as of Mar 25, the value is 14.58. This value exceeds the healthy maximum of 10. It has increased from 14.46 (Mar 24) to 14.58, marking an increase of 0.12.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 14.51. This value is within the healthy range. It has increased from 14.40 (Mar 24) to 14.51, marking an increase of 0.11.
- For Return on Networth / Equity (%), as of Mar 25, the value is 15.42. This value is within the healthy range. It has increased from 15.19 (Mar 24) to 15.42, marking an increase of 0.23.
- For Return on Capital Employeed (%), as of Mar 25, the value is 18.66. This value is within the healthy range. It has decreased from 18.97 (Mar 24) to 18.66, marking a decrease of 0.31.
- For Return On Assets (%), as of Mar 25, the value is 11.74. This value is within the healthy range. It has increased from 11.70 (Mar 24) to 11.74, marking an increase of 0.04.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.01. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.88. It has decreased from 0.89 (Mar 24) to 0.88, marking a decrease of 0.01.
- For Current Ratio (X), as of Mar 25, the value is 4.62. This value exceeds the healthy maximum of 3. It has decreased from 4.78 (Mar 24) to 4.62, marking a decrease of 0.16.
- For Quick Ratio (X), as of Mar 25, the value is 2.85. This value exceeds the healthy maximum of 2. It has decreased from 3.19 (Mar 24) to 2.85, marking a decrease of 0.34.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.58. This value is below the healthy minimum of 4. It has increased from 1.21 (Mar 24) to 3.58, marking an increase of 2.37.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 7.14. This value is below the healthy minimum of 20. It has decreased from 7.22 (Mar 24) to 7.14, marking a decrease of 0.08.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 5.86. This value is below the healthy minimum of 20. It has increased from 5.84 (Mar 24) to 5.86, marking an increase of 0.02.
- For Earning Retention Ratio (%), as of Mar 25, the value is 92.86. This value exceeds the healthy maximum of 70. It has increased from 92.78 (Mar 24) to 92.86, marking an increase of 0.08.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 94.14. This value exceeds the healthy maximum of 70. It has decreased from 94.16 (Mar 24) to 94.14, marking a decrease of 0.02.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 51.37. This value is within the healthy range. It has increased from 45.43 (Mar 24) to 51.37, marking an increase of 5.94.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 33.81. This value is within the healthy range. It has increased from 29.11 (Mar 24) to 33.81, marking an increase of 4.70.
- For Enterprise Value (Cr.), as of Mar 25, the value is 9,417.36. It has increased from 6,244.01 (Mar 24) to 9,417.36, marking an increase of 3,173.35.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.59. This value exceeds the healthy maximum of 3. It has increased from 2.87 (Mar 24) to 3.59, marking an increase of 0.72.
- For EV / EBITDA (X), as of Mar 25, the value is 15.72. This value exceeds the healthy maximum of 15. It has increased from 12.27 (Mar 24) to 15.72, marking an increase of 3.45.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.84. This value exceeds the healthy maximum of 3. It has increased from 3.15 (Mar 24) to 3.84, marking an increase of 0.69.
- For Retention Ratios (%), as of Mar 25, the value is 92.85. This value exceeds the healthy maximum of 70. It has increased from 92.77 (Mar 24) to 92.85, marking an increase of 0.08.
- For Price / BV (X), as of Mar 25, the value is 4.08. This value exceeds the healthy maximum of 3. It has increased from 3.33 (Mar 24) to 4.08, marking an increase of 0.75.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.84. This value exceeds the healthy maximum of 3. It has increased from 3.15 (Mar 24) to 3.84, marking an increase of 0.69.
- For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has decreased from 0.04 (Mar 24) to 0.03, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Marksans Pharma Ltd:
- Net Profit Margin: 14.58%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 18.66% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 15.42% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 33.81
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.85
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 23.7 (Industry average Stock P/E: 51.88)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.01
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 14.58%
Fundamental Analysis of Marksans Pharma Ltd
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 11th Floor, Grandeur, Veera Desai Extension Road, Mumbai Maharashtra 400053 | companysecretary@marksanspharma.com http://www.marksanspharma.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Mark Saldanha | Chairman & Managing Director |
| Mrs. Sandra Saldanha | Whole Time Director |
| Mr. Seetharama R Buddharaju | Independent Director |
| Mr. Abhinna Sundar Mohanty | Independent Director |
| Mr. Digant Mahesh Parikh | Independent Director |
| Mr. Varddhman V Jain | Whole Time Director |
| Mrs. Shailaja Vardhan | Independent Director |
| Dr. Sunny Sharma | Non Executive Director |
Marksans Pharma Ltd. Share Price Update | |
|---|---|
| Share Price | Value |
| Today | ₹165.70 |
| Previous Day | ₹166.80 |
FAQ
What is the intrinsic value of Marksans Pharma Ltd?
Marksans Pharma Ltd's intrinsic value (as of 08 December 2025) is 189.70 which is 3.10% higher the current market price of 184.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 8,337 Cr. market cap, FY2025-2026 high/low of 347/162, reserves of ₹2,643 Cr, and liabilities of 3,442 Cr.
What is the Market Cap of Marksans Pharma Ltd?
The Market Cap of Marksans Pharma Ltd is 8,337 Cr..
What is the current Stock Price of Marksans Pharma Ltd as on 08 December 2025?
The current stock price of Marksans Pharma Ltd as on 08 December 2025 is 184.
What is the High / Low of Marksans Pharma Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Marksans Pharma Ltd stocks is 347/162.
What is the Stock P/E of Marksans Pharma Ltd?
The Stock P/E of Marksans Pharma Ltd is 23.7.
What is the Book Value of Marksans Pharma Ltd?
The Book Value of Marksans Pharma Ltd is 59.3.
What is the Dividend Yield of Marksans Pharma Ltd?
The Dividend Yield of Marksans Pharma Ltd is 0.43 %.
What is the ROCE of Marksans Pharma Ltd?
The ROCE of Marksans Pharma Ltd is 20.0 %.
What is the ROE of Marksans Pharma Ltd?
The ROE of Marksans Pharma Ltd is 16.8 %.
What is the Face Value of Marksans Pharma Ltd?
The Face Value of Marksans Pharma Ltd is 1.00.